Lakefront Biotherapeutics - American Depositary Shares (LKFT)

33.31
-0.08 (-0.24%)
NASDAQ · Last Trade: Nov 22nd, 4:15 PM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close33.39
Open33.61
Bid33.27
Ask33.31
Day's Range33.25 - 33.85
52 Week Range25.68 - 35.54
Volume162,487
Market Cap-
PE Ratio (TTM)-
EPS (TTM)-
Dividend & YieldN/A (N/A)
1 Month Average Volume268,529

Chart

News & Press Releases

Lakefront Biotherapeutics Eyes 2027 Trials for Autoimmune Drug, Backed by €2.2 Billion in Cashmarketbeat.com
Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) is preparing to expand testing of its autoimmune drug candidate gamgertamig, with executives pointing to clinical data, potential registrational trials and a sizable cash balance as the company moves beyond its former cell therapy fo
Via MarketBeat · November 21, 2026
Lakefront Biotherapeutics Targets 2027 Registrational Trials for Gamgertamigmarketbeat.com
Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) said it plans to begin registrational studies next year for its lead T-cell engager, gamgertamig, following a broad restructuring of its legacy cell-therapy operations and the acquisition of assets from Ouro Medicines. Speaking at M
Via MarketBeat · September 21, 2026
Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
Gilead Sciences, Inc. (Nasdaq: GILD) and Lakefront Biotherapeutics NV (Euronext & Nasdaq: LKFT) today announced the successful completion of the previously announced acquisition of Ouro Medicines to advance T cell engager therapies for autoimmune diseases.
By Gilead Sciences, Inc. · Via Business Wire · June 4, 2026
What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launchfool.com
Biotech firm Nektar Therapeutics advances a pipeline of immunology and oncology candidates through research-driven collaborations.
Via The Motley Fool · May 23, 2026
This Healthcare Investor Added $43 Million to a Genomics Leader Growing Volume 34%fool.com
GeneDx Holdings delivers AI-powered clinical and genomic data analysis for healthcare providers seeking precision medicine solutions.
Via The Motley Fool · May 23, 2026